AstraZeneca News

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

May 7 19:34

6-K: Calquence Combination Improved PFS in 1L MCL

May 2 18:53

6-K: Total Voting Rights

May 1 22:29

6-K: Truqap Recommended for EU Breast Cancer Approval

Apr 29 19:22

6-K: Enhertu Improved PFS in HER2-Low and Ultralow

Apr 29 18:52

AstraZeneca | 6-K: Results of Annual General Meeting Held on 11 April 2024

Apr 12 01:25

AstraZeneca | 6-K: AstraZeneca Increases 2024 Dividend by 7%

Apr 11 18:59

AstraZeneca | 6-K: Enhertu Approved in the US as First Tumour-agnostic HER2-directed Therapy for Previously Treated Patients with Metastatic HER2-positive solid Tumours

Apr 8 18:17

AstraZeneca | 6-K: Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

Apr 5 18:27

AstraZeneca | 6-K: Total Voting Rights

Apr 3 01:25

AstraZeneca | 6-K: Voydeya Approved in the Us as Add-On Therapy to Ravulizumab or Eculizumab for Treatment of Extravascular Haemolysis in Adults with the Rare Disease PNH

Apr 2 20:49

AstraZeneca | 6-K: Datopotamab Deruxtecan Biologics License Application Accepted in the Us for Patients with Previously Treated Metastatic HR-Positive, HER2-Negative Breast Cancer

Apr 2 19:59

AstraZeneca | 6-K: Ultomiris Approved in the Us for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder

Mar 25 19:33

AstraZeneca | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

Mar 20 05:34

AstraZeneca | 6-K: Astrazeneca to Acquire Fusion to Accelerate the Development of Next-Generation Radioconjugates to Treat Cancer

Mar 19 18:06

AstraZeneca | 6-K: AstraZeneca to Acquire Amolyt

Mar 14 19:14

AstraZeneca | 6-K: Transaction by Person Discharging Managerial Responsibilities

Mar 12 19:32

AstraZeneca | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Mar 7 19:39

AstraZeneca | 6-K: Notice of Annual General Meeting

Mar 7 19:34

AstraZeneca | 6-K: Astrazeneca Plc Announced That, On 5 March 2024, An Award of the Company's Ordinary Shares of $0.25 Each Vested to Pascal Soriot, Executive Director and Chief Executive Officer, Under the Terms of the Astrazeneca Deferred Bonus Plan

Mar 6 23:13